Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 772

Sort by

Sort Order Select

Journal Articles

Intensive Chemotherapy for High-Risk ALL in Children - the Nordic Collaborative Approach

Atte Nikkilä, MD, Olli Lohi, MD PhD, Ólafur Gísli Jónsson, MD PhD, Bendik Lund, MD PhD, Jonas Abrahamsson, Goda Elizabeta Vaitkeviciene, MD PhD, Kaie Pruunsild, MD, Mats Heyman, MD PhD, Hanne Vibeke Marquart, MD PhD, Kim Vettenranta, MD PhD, Kjeld Schmiegelow, MD PhD

Blood (2019) 134 (Supplement_1): 742.

https://doi.org/10.1182/blood-2019-122914

Published: 2019

Journal Articles

Validation of the Revised AML-Composite Model for the Prediction of Prognosis in Older Patients Receiving Intensive Induction Therapy

Corentin Orvain, Aline Tanguy-Schmidt, Sylvain Thepot, MD, Anne Bouvier, Benedicte Ribourtout, Franck Genevieve, Aurelien Giltat, Marion Champire, Adeline Chanson, Marielle Subileau, Damien Luque Paz, Valerie Ugo, Norbert Ifrah, Mathilde Hunault, MD PhD

Blood (2019) 134 (Supplement_1): 1310.

https://doi.org/10.1182/blood-2019-127351

Published: 2019

Journal Articles

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

Wellington F Silva, MD, Lidiane Inês Da Rosa, MD, Fernanda S Seguro, MD, Douglas R. A. Silveira, Luciana Nardinelli, M.Sc, Valeria Buccheri, MD PhD, Elvira DRP Velloso, MD PhD, Vanderson Rocha, MD PhD, Eduardo M Rego, MD PhD

Blood (2019) 134 (Supplement_1): 1354.

https://doi.org/10.1182/blood-2019-127202

Published: 2019

Journal Articles

A Multicenter Randomized Non-Inferiority Study of Homoharringtonine Versus Etoposide in Induction Phase for Chinese Childhood Acute Myeloid Leukemia - a Report from China Children's Leukemia Group (CCLG)

Blood (2019) 134 (Supplement_1): 1356.

https://doi.org/10.1182/blood-2019-127932

Published: 2019

Journal Articles

Prospective Evaluation of Allogeneic HSCT at the First Remission for Younger Adults with FLT3 -ITD Positive Acute Myeloid Leukemia: The JALSG AML209-FLT3-SCT Study

Blood (2019) 134 (Supplement_1): 1328.

https://doi.org/10.1182/blood-2019-124394

Published: 2019

Journal Articles

Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

Blood (2019) 134 (Supplement_1): 1358.

https://doi.org/10.1182/blood-2019-125262

Published: 2019

Journal Articles

Hematologic Recovery from Venetoclax-Containing Regimens in Relapsed/Refractory Acute Myeloid Leukemia Patients Depending on Prior Allogeneic Hematopoietic Cell Transplantation

Rabia Shahswar, MD, Gernot Beutel, MD, Piroska Klement, Alina Rehberg, Razif Gabdoulline, Christian Koenecke, MD, Dominik Markel, MD, Hendrik Eggers, MD, Matthias Eder, MD, Michael Stadler, MD PhD, Lothar Hambach, MD, Steve Ehrlich, MD, Gudrun Gohring, MD, Brigitte Schlegelberger, MD, Arne Trummer, MD, Juergen Krauter, MD, Arnold Ganser, MD, Felicitas Thol, MD, Michael Heuser, MD

Blood (2019) 134 (Supplement_1): 1359.

https://doi.org/10.1182/blood-2019-125377

Published: 2019

Journal Articles

Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions

Aaron D Goldberg, MD PhD, Catherine C. Coombs, MD, Eunice S. Wang, MD, Roland B. Walter, MD PhD MS, Chatchada Karanes, MD, Carlos Enrique Vigil, MD, Boo Messahel, MD, Richard M. Stone, MD, Robert H. Collins, MD

Blood (2019) 134 (Supplement_1): 1326.

https://doi.org/10.1182/blood-2019-130863

Published: 2019

Journal Articles

Epigenetic Priming with Decitabine Followed By Low-Dose Idarubicin Plus Cytarabine in AML Evolving from MDS or Higher Risk MDS: A Multicentre Phase 2 Single-Arm Trial

Hongyan Tong, Docter, Xinping Zhou, Chen Mei, Jin Zhang, Ying Lu, Jianping Lan, MD, Shengyun Lin, Yuefeng Zhuang, Yuemin Kuang, Yanling Ren, Liya Ma, Juying Wei, Li Ye, Weilai Xu, Kongfei Li, Chenxi Lu, Jie Jin, MD PhD

Blood (2019) 134 (Supplement_1): 2594.

https://doi.org/10.1182/blood-2019-127675

Published: 2019

Journal Articles

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Daniel J. DeAngelo, MD PhD, Harry P. Erba, MD PhD, Brian A Jonas, MD PhD, Michael E O'Dwyer, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Gerwin Huls, MD PhD, Jane L. Liesveld, MD, Brenda Cooper, MD, Bhavana Bhatnagar, DO, Geoffrey L. Uy, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Michael B. Armstrong, MD PhD, William E. Fogler, PhD, Mary M Chen, MD PhD, John L. Magnani, PhD, Helen M Thackray, MD, Eric J. Feldman, MD, Anjali S. Advani, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2650.

https://doi.org/10.1182/blood-2019-123816

Published: 2019

Journal Articles

Combination of Tigecycline and Homoharringtonine Synergistically Enhances Anti-Leukemia and Anti-MDS Effect Followed By Inhibiting Mitochondrial Translation through AKT/Mtorpathway and Downregulation of Anti-Apoptotic Proteins

Jie Jin, MD PhD, Hongyan Tong, Yang Haiyang

Blood (2019) 134 (Supplement_1): 5387.

https://doi.org/10.1182/blood-2019-128171

Published: 2019

Journal Articles

Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)

Tomoyuki Tanaka, Kiyomi Morita, MD, Feng Wang, PhD, Latasha Little, Curtis Gumbs, Jairo Matthews, Courtney D. DiNardo, MDMSc, Tapan M. Kadia, MD, Farhad Ravandi, MD, Marina Y Konopleva, MD PhD, Hagop M. Kantarjian, MD, Richard E. Champlin, MD, Guillermo Garcia-Manero, MD, P Andrew Futreal, PhD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 17.

https://doi.org/10.1182/blood-2019-122274

Published: 2019

Journal Articles

High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3

Bhaskar Kolla, MBBS, Nurul Aidah Abdul Halim, MBBS, Zohar Sachs, MD PhD, Erica D. Warlick, MD, Daniel J. Weisdorf, MD, Fiona He, MD, Lao Zhentang, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 3432.

https://doi.org/10.1182/blood-2019-123306

Published: 2019

Journal Articles

High Dose Flamsa, CLAG or FLAG-Based Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasia Patients: A Multicenter Study in Singapore

Yin Jie Koh, Michelle Poon, MBBS, MRCP, FRCPATH, Yeh Ching Linn, MBBS, MRCP, William YK Hwang, MBBS, FRCP, Elson Neo, Aloysius YL Ho, MBBS,FRCP,FRCPath, Lip Kun Tan, MBBS, FRCP, FRCPath, Liang Piu Koh, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 4509.

https://doi.org/10.1182/blood-2019-125246

Published: 2019

Journal Articles

Streamline - Study of Relapse or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study

Amer M. Zeidan, MBBS, MHS, Adrienne Gilligan, PhD, Santosh Gautam, Nan Hu, David L. Grinblatt, Bhavik J. Pandya, PharmD

Blood (2019) 134 (Supplement_1): 5082.

https://doi.org/10.1182/blood-2019-123535

Published: 2019

Journal Articles

DNA Repair Genes' Expression Abnormalities in De Novo Acute Myelogenous Leukemia (AML): Implications for Targeted Treatment

Frieda Kontsioti, PhD, Eirini Maratou, PhD, Anthi Bouhla, MD, Vassiliki Mpakou, PhD, Konstantinos Gkodopoulos, MD, Georgia Stavroulaki, MD, Eirini Glezou, MD, Thomas Thomopoulos, MD, Efthimia Bazani, MD, Sotirios Papageorgiou, MD PhD, Argiris Symeonidis, MD PhD, George Dimitriadis, MD, Vassiliki Pappa, MD

Blood (2019) 134 (Supplement_1): 5176.

https://doi.org/10.1182/blood-2019-127501

Published: 2019

Journal Articles

Improved Outcomes of All-Trans-Retinoic Acid and Arsenic Trioxide Plus Idarubicin As a Frontline Treatment in Adult Patients with Acute Promyelocytic Leukemia

Shiwei Yang, Zunmin Zhu, Xiaojian Zhu, Yicheng Zhang

Blood (2019) 134 (Supplement_1): 5088.

https://doi.org/10.1182/blood-2019-128602

Published: 2019

Journal Articles

CBFA2T3-GLIS2 Fusion Gene Cause Dismal Clinical Course in Acute Megakaryocytic Leukemia of Down Syndrome

Nao Takasugi, Kenichi Amano, Yasuo Kubota, MD, Shota Kato, MD, Yuichi Mitani, MD, Junya Fujimura, MD PhD, Junko Takita, MD PhD, Mitsuteru Hiwatari, MD PhD

Blood (2019) 134 (Supplement_1): 5184.

https://doi.org/10.1182/blood-2019-129165

Published: 2019

Journal Articles

FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial

Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Daniel Slade, MSc, BSc (Hons), Jenny Byrne, MD PhD, Kristian Brock, MSc, BSc, Hugues De Lavallade, Charles Craddock, FRCP, FRCPath, Richard Clark, MBBS, MRCP, MRCPath, MD, Matthew Smith, MBBS, Rebecca Bishop, BSc, Dragana Milojkovic, MBBS, MD, Christina Yap, MSci, PhD CStat

Blood (2019) 134 (Supplement_1): 497.

https://doi.org/10.1182/blood-2019-125591

Published: 2019

Journal Articles

Efficacy and Safety of DAC Combined with CAG Regimen (decitabine in combined with aclacinomycin, cytarabine and G-CSF) As a Second Induction Regimen Compared with Non-DAC Regimen for Acute Myeloid Leukemia Who Failed the First Course of Standard Induction IA Chemotherapy

Yili Chen, Min Dai, Qifa Liu, MD

Blood (2019) 134 (Supplement_1): 5104.

https://doi.org/10.1182/blood-2019-127947

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Intensive Chemotherapy for High-Risk ALL in Children - the Nordic Collaborative Approach

Validation of the Revised AML-Composite Model for the Prediction of Prognosis in Older Patients Receiving Intensive Induction Therapy

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

A Multicenter Randomized Non-Inferiority Study of Homoharringtonine Versus Etoposide in Induction Phase for Chinese Childhood Acute Myeloid Leukemia - a Report from China Children's Leukemia Group (CCLG)

Prospective Evaluation of Allogeneic HSCT at the First Remission for Younger Adults with FLT3 -ITD Positive Acute Myeloid Leukemia: The JALSG AML209-FLT3-SCT Study

Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

Hematologic Recovery from Venetoclax-Containing Regimens in Relapsed/Refractory Acute Myeloid Leukemia Patients Depending on Prior Allogeneic Hematopoietic Cell Transplantation

Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions

Epigenetic Priming with Decitabine Followed By Low-Dose Idarubicin Plus Cytarabine in AML Evolving from MDS or Higher Risk MDS: A Multicentre Phase 2 Single-Arm Trial

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Combination of Tigecycline and Homoharringtonine Synergistically Enhances Anti-Leukemia and Anti-MDS Effect Followed By Inhibiting Mitochondrial Translation through AKT/Mtorpathway and Downregulation of Anti-Apoptotic Proteins

Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)

High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3

High Dose Flamsa, CLAG or FLAG-Based Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasia Patients: A Multicenter Study in Singapore

Streamline - Study of Relapse or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study

DNA Repair Genes' Expression Abnormalities in De Novo Acute Myelogenous Leukemia (AML): Implications for Targeted Treatment

Improved Outcomes of All-Trans-Retinoic Acid and Arsenic Trioxide Plus Idarubicin As a Frontline Treatment in Adult Patients with Acute Promyelocytic Leukemia

CBFA2T3-GLIS2 Fusion Gene Cause Dismal Clinical Course in Acute Megakaryocytic Leukemia of Down Syndrome

FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial

Efficacy and Safety of DAC Combined with CAG Regimen (decitabine in combined with aclacinomycin, cytarabine and G-CSF) As a Second Induction Regimen Compared with Non-DAC Regimen for Acute Myeloid Leukemia Who Failed the First Course of Standard Induction IA Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only